NH700955 120224

	EMERGENCY DEPARTMENT ADULT VTE RISK ASSESSMENT
	SR
ast	ARTMENT ASSESSMENT
ole,	

SMR040.012

NSW Health		FAMILY NAME		MRN				
		GIVEN NAME		☐ MALE ☐	FEMALE			
GOVERNMENT Facility:			M.O.					
r acmty.	ADDRE	ESS	1					
EMERGENCY DEPARTMENT								
ADULT VTE RISK ASSESSMENT	LOCATION / WARD							
ADOLI VIL NIGITAGGLOGINLIVI	C	COMPLETE ALL DETAILS	OR AFFIX PA	ATIENT LABEL	HERE			
EMERGENCY DEPARTMENT ADULT VENOUS THROMBOEMBOLISM (VTE) RISK ASSESSMENT TOOL For adult patients (> 16 years) being discharged from the Emergency Department with an isolated lower limb injury requiring temporary lower limb immobilisation.								
1a. Does the patient have any of the following treatme		<u> </u>						
☐ Ankle or knee immobilisation, short or long backslab or plaster cast, CAM boot, knee brace or equinus slab ☐ Directed not to fully weight bear								
1b. Does the patient have any of the following patient	t relate	d VTE risk factors? (Tic	k those tha	t apply)				
Prior history of VTE								
Known thrombophilia (including inherited disorders)Active malignancy or cancer treatment								
Obesity (BMI > 30 kg/m²)								
☐ Age > 60 years ☐ Hormonal risk factors: hormonal replacement therapy,	nestro	gen-hased contracentives	nregnant o	r < 6 weeks nos	t-nartum			
(refer to Obstetrics Consultant / Team prior to commen	cing ph	armacological prophylaxi	s)					
Other medical conditions associated with VTE risk: my heart failure, active or chronic lung disease, active infec								
nephrotic syndrome, dehydration, varicose veins/chroni 1c. Pharmacological prophylaxis decision					·			
Does the patient meet either of the following critera:	10	Does the patient related risk factor						
Both treatment related VTE risk factors?	10	patient related V						
OR								
OR			VEC					
One treatment related AND one			YES					
		sider VTE prophylaxis on	an individua	al patient basis				
One treatment related AND one or more patient related VTE risk	□ F	sider VTE prophylaxis on Prophylaxis is considered Continue onto Section 2)	an individua	al patient basis				
One treatment related AND one or more patient related VTE risk factors?	☐ F	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT consid	an individua appropriate	·				
One treatment related AND one or more patient related VTE risk factors? YES	☐ F	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Encourage early mobiled Provide patient educated	an individua appropriate dered approp isation ion	oriate				
One treatment related AND one or more patient related VTE risk factors?	☐ F	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Encourage early mobil	an individua appropriate dered approprisation ion available on	oriate				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis	F ('	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Encourage early mobiled Provide patient educate (patient information is a VTE Prevention webpare	an individua appropriate dered approprisation ion available on	oriate				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2)	F ((Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Encourage early mobiled Provide patient educate (patient information is a VTE Prevention webpare	an individua appropriate dered approprisation ion available on age)	oriate the CEC's				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat	F (Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Encourage early mobiled Provide patient educate (patient information is a VTE Prevention webpatharmacological Prophylaxis is a part of the prophylaxis in the prophylaxis is a part of the prophylaxis in the prophylaxis is a part of the prophylaxis in the prophylaxis is a part of the prophylaxis in the prophylaxis is considered.	an individua appropriate dered approprisation ion available on age)	the CEC's				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban)	F (Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue on Consideration and Continue on Continue	an individua appropriate dered approprisation ion available on age) laxis (Consider ris	the CEC's k vs benefit)				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Provide patient educat (patient information is a VTE Prevention webpater of the Contraindication of Contr	an individual appropriate dered appropriate dered appropriation ion available on age) laxis (Consider rise age within laweeks thin 2 weeks	the CEC's k vs benefit) ast year	within last			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban)	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue on Consideration and Continue on Continue	an individual appropriate dered appropriate dered appropriation ion available on age) laxis (Consider rise age within laweeks thin 2 weeks	the CEC's k vs benefit) ast year	within last			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulor	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Contrained Educat (patient information is a VTE Prevention webpath armacological Prophylam Contrained Cont	an individua appropriate dered appropriate dered appropriation ion available on age) laxis (Consider risage within laweks thin 2 weeks enitourinary cons/neoplas	the CEC's k vs benefit) ast year haemorrhage v	within last			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulor	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Provide patient educat (patient information is a VTE Prevention webpath of the Prevention websath of the Prevention w	an individua appropriate dered appropriate dered appropriate dered appropriation ion available on age) laxis (Consider rise age within layeeks thin 2 weeks enitourinary ons/neoplasency	the CEC's the Vs benefit) ast year haemorrhage verses	within last			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulor	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue on Considered Contraction is a Continue on Con	an individual appropriate dered appropriate dere	the CEC's k vs benefit) st year haemorrhage vers				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulor	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Encourage early mobil Provide patient educat (patient information is a VTE Prevention webpater electric encourage early mobil Provide patient educat (patient information is a VTE Prevention webpater electric el	an individual appropriate dered appropriate dere	the CEC's k vs benefit) st year haemorrhage vers				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulor	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue on Considered Contraction is a Continue on Con	an individual appropriate dered appropriate dere	the CEC's k vs benefit) st year haemorrhage vers				
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulor	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2 Provide patient educat (patient information is a VTE Prevention webparant of the Prevention websarant of the Prevention websarant of the Prevention web	an individual appropriate dered appropriate dere	the CEC's k vs benefit) st year haemorrhage vectoring the series of the cord, with haem	yridamole,			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulogory Other:	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue on Considered Contraint educat (patient information is a VTE Prevention webparature of Continue on Contraint on Contr	an individual appropriate dered appropriate dere	the CEC's k vs benefit) st year haemorrhage vectoring the series of the cord, with haem	yridamole,			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulogouther: Other:	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue on Consideration of Continue Contraindication of Contraindication	an individua appropriate dered	the CEC's k vs benefit) st year haemorrhage vectoring dipy cord, with haem 5)	yridamole, orrhage			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 10 ⁹ /L) OR coagulog Other: Other: Other Considerations Heparin-sensitivity or history of heparin-induced thrombe e.g. danaparoid use)	ns to P	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Contrained Contrai	an individua appropriate dered	the CEC's k vs benefit) st year haemorrhage vectoring dipy cord, with haem 5)	yridamole, orrhage			
One treatment related AND one or more patient related VTE risk factors? YES Recommend VTE prophylaxis (Continue onto Section 2) 2. Identify Contraindications and Other Consideration Absolute Contraindication Therapeutic anticoagulation (e.g. with warfarin, dabigat rivaroxaban, fondaparinux, apixaban) Active haemorrhage Thrombocytopenia (platelets < 50 x 109/L) OR coagulogouther: Other:	ns to P tran, pathy cocytopons ove	Prophylaxis is considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Continue onto Section 2) Prophylaxis is NOT considered Contrained Control in Information is a VTE Prevention webparate Contrained Control in Intracranial haemorphylamical Control in Intracranial lesi Control in Interited bleeding discontrol in Interited bleeding discontrol in Interited Severe trauma to hea Control in Interited Severe trauma to hea Control in Interited Severe Interior I	an individual appropriate dered appropriate dere	the CEC's k vs benefit) ast year haemorrhage very series clopidogrel, dipy cord, with haem b)	yridamole, orrhage ment			

NO WRITING Page 1 of 2

NSW Health		YNAME	MRN					
		N NAME	☐ MALE ☐ FEMALE					
		//						
Facility:		ADDRESS						
EMERGENCY DEPARTMENT		TION / WARD						
ADULT VTE RISK ASSESSMENT	200/	COMPLETE ALL DETAILS	OR AFFIX F	PATIENT I ABEL HERE				
ANY CONTRAINDICATIONS OR OTHER CONSIDERAT	IONS							
YES - Refer to absolute contraindication identified or relative contraindication/other considerations identified NO - Continue on to Section 3								
Absolute contraindication identified		Relative contraindication	n/Other co	nsiderations identified				
□ DO NOT prescribe VTE prophylaxis□ Encourage early mobilisation□ Provide patient education		Seek relevant senior medical staff advice before prescribing						
If patient is at risk of VTE and contraindications/other	cond	litions (if present) have b	een assess	sed, CONTINUE:				
3. Order blood tests Order: FBC EUC PT/APTT If possible, patient should wait in ED until results are returned. If results cannot be accessed in a timely manner, refer the patient for next day follow up.								
4. Prescribe appropriate VTE prophylaxis								
Select one option: Enoxaparin 40 mg subcutaneous daily Enoxaparin 20 mg subcutaneous daily if Creatinine Clearance < 30 mL/min DO NOT prescribe VTE Dother: Tother: Select one option: Enoxaparin 20 mg subcutaneous daily if Creatinine Clearance < 30 mL/min If Creatinine Clearance is < 15 mL/min seek specialist advice regarding an alternative treatment Other: Give self-injection demonstration and administer first dose THEN (Select relevant question below) Patient or patient's carer is able to manage injections Provide CEC patient education sheet								
		Provide Clexane administration education sheet						
Patient/carer CANNOT manage injections		Refer to Outpatient Services (e.g. Community Nursing, Ambulatory Care Units)						
6. Communicate information about ongoing management and monitoring to the relevant healthcare professional								
Discharge procedure: ☐ Provide patient education including written information ☐ Administer first dose of medication ☐ Provide take home pack of medication or access to su ☐ Provide sharps bin ☐ Provide letter to GP - including request to repeat FBC ☐ Arrange appropriate follow-up: Fracture clinic or GP ☐ Provide patient discharge paperwork ☐ Other:	apply	EUC in 7 days						
Therapy for lower leg immobilisation due to injury should continue until mobility returns to normal								
Name Signature								
Designation		Date:/	/					



Page 2 of 2 NO WRITING